Delving into the Latest Updates on Hangzhou Paqisi Pharmaceutical Technology Co., Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

5-HT3 receptor(Serotonin 3 (5-HT3) receptor)	1

主要目的： 1．评估健康中国成年受试者单次给予盐酸雷莫司琼缓释贴片后的安全性、耐受性。次要目的： 1．评估健康中国成年受试者单次给予盐酸雷莫司琼缓释贴片后体内药代动力学特征。 2．评估健康中国成年受试者单次给予盐酸雷莫司琼缓释贴片后，该贴片的粘附性。

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of the ramosetron hydrochloride sustained-release patch after a single administration to healthy Chinese adult subjects. Secondary objectives: 1. To evaluate the in vivo pharmacokinetic characteristics of the ramosetron hydrochloride sustained-release patch after a single administration to healthy Chinese adult subjects. 2. To evaluate the adhesion of the ramosetron hydrochloride sustained-release patch after a single administration to healthy Chinese adult subjects.

Start Date-

Sponsor / Collaborator

Zhejiang Academy of Medical Sciences

[+1]

100 Clinical Results associated with Hangzhou Paqisi Pharmaceutical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Paqisi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Paqisi Pharmaceutical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Paqisi Pharmaceutical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data